黄芪对血液透析患者氧化应激的影响

目的：了解维持性血液透析（maintenance hemodialysis，MHD）患者的氧化应激及微炎症状态，观察黄芪对其的影响。 方法：选取60例MHD患者随机分为2组，在透析过程中给予（治疗组）或不予（对照组）黄芪注射液治疗12周，另选取年龄和性别匹配的健康成年志愿者10例为健康人组。荧光分光光度法测定血浆晚期糖基化终末产物（advanced glycation end products，AGEs）、晚期蛋白质氧化产物（advanced oxidation protein product，AOPP）、脂氧化终末产物丙二醛（malondialdehyde，MDA）及维生素E（vitamin E，VitE）含量；酶联免疫吸附法（enzyme-linked immunosorbent assay，ELISA）测定血浆C反应蛋白（C-reactive protein，CRP）含量。 结果：与健康人比较，MHD患者血浆AGEs、AOPP、MDA和CRP含量显著升高（P＜0．01），VitE含量显著降低（P〈0．01）；黄芪注射液治疗12周后，MHD患者血浆AGEs、AOPP、MDA和CRP含量明显下降（P〈0．05，P〈0．01），VitE浓度无变化（P〉0．05）。 结论：MHD患者存在明显的氧化应激及微炎症状态；黄芪注射液可在一定程度上降低其氧化产物的蓄积，减轻微炎症状态。但减少抗氧化剂VitE丢失的作用不明显．

Effects of Astragalous Injection on oxidative stress status in maintenance hemodialysis patients

OBJECTIVE: To analyze the effects of Astragalous Injection on oxidative stress and micro-inflammatory status in patients undergoing maintenance hemodialysis (MHD). METHODS: Sixty MHD patients were included and randomized into treatment group and control group, with another 10 healthy volunteers as normal control. The patients in the treatment group were treated with Astragalous Injection and the patients in the control group were treated with normal saline for 12 weeks. A spectrophotometric method was used for the measurement of plasma concentrations of oxidative parameters including advanced glycation end products (AGEs), advanced oxidation protein product (AOPP), malondialdehyde (MDA) and vitamin E (Vit E). The content of C-reactive protein (CRP) was evaluated by enzyme-linked immunosorbent assay. RESULTS: Compared with the normal control group, the plasma levels of AGEs, AOPP, MDA and CRP were significantly increased, while plasma level of Vit E was significantly decreased in MHD patients ( P<0.01). After Astragalous Injection treatment, the plasma levels of AGEs, AOPP, MDA and CRP were decreased as compared with the control group ( P<0.01), while there was no significant difference in plasma Vit E level between the treatment group and control group. CONCLUSION: There exist oxidative stress and micro-inflammation in MHD patients. Astragalous Injection can ameliorate the accumulation of oxidative products and micro-inflammatory status, but it has no significant effect on plasma Vit E level.